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BRIEF DEFINITIVE REPORT
        Chronic infl  ammatory joint and intestinal diseases 
are often coexpressed in individual patients, in-
dicating common underlying pathogenic mecha  -
nisms. Epidemiological studies revealed that a 
substantial group of patients suff  ering from spondy-
loarthritis shows asymptomatic gut infl  ammation, 
and some of them (7%) eventually develop in-
fl  ammatory bowel disease (IBD), particularly 
Crohn  ’  s disease (CD) ( 1, 2 ). Conversely, spon-
dyloarthritis is not uncommonly associated with 
IBD (  3  ). The coexistence of these diseases is 
usually classifi  ed in the group of spondyloar-
thropathies (SpAs) and is defi  ned as interrelated 
and overlapping chronic infl  ammatory  diseases 
that mainly include ankylosing spondylitis, reac-
tive and psoriatic arthritis, and CD (  4  ). 
  Spondyloarthritis, rheumatoid arthritis, and 
CD are diseases showing major clinical re-
sponses to anti-TNF treatment (  5, 6  ). An im-
portant fi  nding validating the role of TNF in 
specifi  cally driving infl  ammatory arthritis in vivo 
was provided by the generation of transgenic 
mice overexpressing human TNF (  Tg197   mice) 
and developing chronic infl  ammatory polyar-
thritis, which was reversible by anti –  human TNF 
antibody administration (  7  ). More recently, it 
was recognized that   Tg197   mice also develop 
spondyloarthritis ( 8  ). Importantly, a previously es -
tablished TNF-overexpressing mouse model 
(  Tnf      ARE     mice) characterized by the develop-
ment of both chronic infl  ammatory polyarthritis 
and Crohn  ’  s-like IBD (  9  ) is shown in this report 
to also develop extraintestinal features of spondy-
loarthritis such as sacroiliitis and enthesitis. These 
results establish   Tnf      ARE     mice as a new model for 
SpAs uniquely associated with CD (similarly to 
human SpAs), off  ering an appropriate system in 
which further mechanistic studies, including a 
potential common basis of TNF function in these 
pathologies, can be explored. 
  Mechanistic hypotheses addressing the co-
incidence of gut  –  joint axis diseases in humans 
favor an aetiopathogenic role for common mo-
lecular determinants on eff  ector lymphocytes, 
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(TNFRI) expression in the radiation-resistant compartment, which is also known to be a 
suffi  cient target of TNF in the development of Crohn  ’  s-like IBD in the same model. Early 
activation of synovial fi  broblasts and intestinal myofi  broblasts could also be demonstrated 
by perturbed expression of matrix metalloproteases and their inhibitors. Notably, selective 
Cre/loxP-mediated TNFRI expression in mesenchymal cells resulted in a fully arthritic  –  spondylo-
arthritic and intestinal phenotype, indicating that mesenchymal cells are primary and suffi  cient 
targets of TNF in these pathologies. Our results offer a novel mechanistic perspective for TNF 
function in gut and joint pathologies and indicate early common cellular pathways that may 
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poietic or radiation-resistant tissue stromal cells. Using this 
system, we have previously reported the capacity of BM-
derived cells from the   Tnf       ARE     mice to induce IBD and, 
more importantly, that radiation-resistant, tissue stroma  –  re-
siding cells are suffi   cient TNF targets for the induction of 
IBD (  12  ). We have now extended these previous fi  ndings 
by demonstrating that at 12 wk after transplantation, lethally 
irradiated WT mice transplanted with   Tnf       ARE/+     BM cells 
also develop arthritis (  Table I  ; and Fig. S1 A, available at 
http://www.jem.org/cgi/content/full/jem.20070906/DC1), 
indicating that a source of pathogenic TNF production in 
this model resides within the hematopoietic compartment.   
Transfer of   Tnf      ARE/    ARE   TnfRI      /        BM into WT irradi-
ated recipients resulted in overt arthritis, similar to the 
  Tnf       ARE/+    -reconstituted WT mice, as indicated by histo  patho-
logical analysis of joints performed 12 wk after engraftment 
(  Table I   and Fig. S1 B), suggesting that radiation-resistant, 
stroma  –  residing cells are suffi   cient TNF targets for the in-
duction of arthritis. Reciprocal engraftment of   Tnf      ARE/+     
BM into   TnfRI      /        recipients did not result in any arthritic 
manifestation 12 wk after transplantation (  Table I   and Fig. 
S1 C), indicating that radiation-resistant, tissue stroma  – 
residing cells are also required TNF targets for the induc-
tion of arthritis. Similar results were obtained using the 
huTNF transgenic   Tg197   model of arthritis (unpublished 
data). Collectively, these results demonstrate that in TNF-
mediated arthritis, TNFRI expression on radiation-resistant 
cells is a necessary and suffi   cient condition for the develop-
ment of disease. 
  Early activation of mesenchymal cells in modeled arthritis 
and Crohn  ’  s-like IBD 
  In infl  amed tissues, mesenchymal cells become activated and 
act as both recruiters of lymphocytes, by the increased ex-
pression of adhesion molecules (  15, 16  ), and as eff  ectors of 
tissue destruction, through the production of several matrix 
degrading enzymes such as matrix metalloproteinases (MMPs) 
(  17, 18 ). Importantly, TNFRI-mediated mesenchymal MMP 
secretion in human fetal small intestine explant cultures has 
been previously associated with intestinal injury (  19  ). To exam-
ine whether mesenchymal cells of   Tnf      ARE     mice are activated 
before the onset of disease, we isolated synovial fi  broblasts 
(SFs) of ankle joints and intestinal myofi  broblasts (IMFs) 
from WT and   Tnf      ARE/+     mice before the appearance of the 
infl  ammatory infi  ltrate (at 4 wk of age) (  9, 12  ). Increased pro-
teolytic activity against gelatin caused by MMP9 expression 
was detected in SF and IMF cell extracts in contrast to MMP2 
activity, which remained unaltered (  Fig. 2 A  ).   Additionally, 
semiquantitative RT-PCR revealed the up-regulation of 
MMP3 and the strong down-regulation of tissue inhibitor of 
MMPs 1 (TIMP1) messenger RNA, leading to severely mis-
balanced ratios of MMP3 versus TIMP1 expression in both SF 
and IMF cells of   Tnf      ARE/+     compared with WT mice (  Fig. 2 B  ). 
Furthermore, using immunofl  uorescent staining of ex vivo  –
  derived SFs and IMFs, we detected elevated protein expres-
sion of MMP3 and MMP9 in   Tnf      ARE     cultures (Fig. S2, 
which render them capable of homing equally effi   ciently to 
the intestinal mucosa and joints (  10  ). An experimental model 
in support of this hypothesis, the HLA-B27 transgenic rat, a 
spontaneous model for SpAs, develops colitis, gastritis, and 
arthritis (  11  ). Although adaptive immune responses and, 
more specifi  cally, CD8  +   eff  ector function are required for the 
development of Crohn  ’  s-like IBD in the   Tnf       ARE     model 
(  12  ), arthritis develops independently of the adaptive im-
mune compartment (  9  ), indicating that T cell responses may 
not be commonly required in the pathogenesis of these two 
diseases. Therefore, alternative mechanisms are likely to be 
responsive for TNF-mediated pathology in gut  –  joint dis-
eases. Current hypotheses suggest that TNF delivers innate 
activation and proinfl  ammatory signals through its action on 
various cell types, including myeloid/monocytic, lympho-
cytic, endothelial, mesenchymal, or epithelial cell types (  5, 
13  ). Using TNF-driven disease models, we demonstrate for 
the fi  rst time that mesenchymal cells, such as the fi  broblasts/
myofi  broblasts of the joint and the intestine, are primary re-
sponder cells suffi   cient for full pathogenic TNF/TNFRI sig-
naling in arthritis, sacroiliitis, and Crohn  ’  s-like IBD. Our 
fi  ndings provide novel mechanistic insights into the cellular 
and molecular events underlying TNF function in joint  –  gut 
axis diseases and establish an early dominant role for mesen-
chymal cell responses in their pathogenesis. 
    RESULTS AND DISCUSSION   
    Tnf      ARE     mice as a model for SpAs 
    Tnf      ARE/+     mutant mice have been described previously (  9, 12  ) 
to develop chronic polyarthritis starting at weeks 5  –  6 and 
Crohn  ’  s-like IBD starting at week 6. Prompted by the coinci-
dence of both joint and intestinal disease in these mice, we 
have examined whether additional features of spondyloar-
thritic disease are developing in this model. Histological anal-
ysis of sacroiliac joints from   Tnf      ARE/+     mice revealed bilateral 
infl  ammation of the sacroiliac joints, a prominent feature of 
ankylosing spondylitis. Invasion of infl  ammatory tissue was 
detected in the subchondral bone and iliac BM of   Tnf       ARE/+     
mice (  Fig. 1  ).   Initial signs of enthesitis were evident by week 4 
(not depicted). No gender bias was apparent. These data es-
tablish   Tnf      ARE     mutant mice as a disease model resembling 
human SpAs. Interestingly, the   Tnf      ARE     model is characterized 
by the combined presence of arthritis  –  spondyloarthritis with 
a CD-like pathology localized primarily in the small intestine, 
as typically occurs in patients suff  ering from SpAs (  2  ). 
  TNFRI expression on radiation-resistant, tissue 
stroma  –  residing cells is necessary and suffi  cient 
for the induction of arthritis 
  The dominant role of TNFRI in mediating TNF patho-
genic signals in modeled arthritis and IBD has been pre-
viously established (  7, 9  ). To gain further insight into the 
cellular specifi  city of TNFRI-mediated signaling, we used 
BM engraftment experiments into lethally irradiated recipi-
ents, using TNFRI-defi  cient mice (  14  ) as either recipients 
or donors, to restrict TNFRI expression in either hemato-JEM VOL. 205, February 18, 2008  333
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collagen VI (ColVI) promoter cassette (Fig. S3 A, available at 
http://www.jem.org/cgi/content/full/jem.20070906/DC1), 
which is known to drive gene expression in mesenchymal 
cell types ( 20  ). The specifi  city of Cre-mediated recombi   nation 
in the  ColVI-Cre   mice was assessed using the  ROSA26   and  Z/
EG   reporter mouse strains (  21, 22  ). X-gal staining in various 
tissues of   ColVI-Cre ROSA26   fl x / +     mice indicated Cre-medi-
ated recombination in joint SFs, articular chondrocytes and 
myocytes, skin keratinocytes and dermal fi  broblasts, the mus-
cle layer around arteries of the heart (not depicted), and under-
neath the epithelial layer of the gut (Fig. S3, B –  E). Cre activity 
was not detected in hematopoietic tissues (spleen and thymus; 
not depicted). Effi   ciency of Cre-mediated recombination in 
ex vivo  –  cultured SFs measured by fl  ow cytometric analy-
sis using fl  uorodeoxyglucose staining was   >  80% (Fig. S3 F). 
The localization of X-gal  –  positive cells neighboring the epi-
thelium of   ColVI-Cre ROSA26   fl x / +     reporter mice indicated 
Cre recombinase expression in the subepithelial myofi  bro-
blast cell layer (Fig. S3, D and E). Indeed, in   ColVI-Cre Z/EG   
mice (  22  ), GFP-expressing cells stained positive for      SMA 
(Fig. S3, J  –  L) but negative for the CD31 endothelial cell marker 
(Fig. S3, G  –  I), indicating Cre-mediated recombination in 
subepithelial myofi  broblasts. 
  To obtain mesenchymal cell  –  specifi  c expression of TNFRI, 
we used previously generated mutant mice carrying a con-
ditional gain-of-function allele for this receptor   (TnfRI  fl  xneo     
mice). In these mice, TNFRI expression is inhibited by the 
presence of a fl  oxed neomycin cassette but is restored upon 
Cre-mediated neo excision (  23  ). The specifi  city of recombi-
nation for the fl  oxed neo TNFRI allele was examined in 
A and B, respectively, available at http://www.jem.org/cgi/
content/full/jem.20070906/DC1). Interestingly, we detected 
       –  smooth muscle actin (     SMA) expression by SFs as well as 
IMFs (Fig. S2 C), suggesting common phenotypic features 
between these two cell types. These results indicate that mes-
enchymal/myofi  broblast-like cells of   Tnf      ARE     mice may rep-
resent the local primary targets of TNF in the induction of 
joint and gut pathology. Misbalanced production of MMPs and 
TIMPs by SFs and IMFs confi  rms early proinfl  ammatory trig-
gering that could potentially promote primary matrix degra-
dation in the respective tissues. 
  TNFRI-expressing mesenchymal cells are suffi  cient TNF 
targets for the development of SpA-related pathologies 
  To investigate the specifi  c role of mesenchymal cells in the 
  Tnf      ARE     and   Tg197   pathologies, we generated transgenic 
mice expressing Cre recombinase under the control of a 
    Figure 1.         Bilateral infl  ammation in sacroiliac joints of   Tnf      ARE     mice.   (A  –  C) Sacroiliac joint from a healthy C57BL/6 control. The lower two thirds of 
the joint consists of fi  brocartilagenous tissue, and it is well defi  ned and separated from the periost of the iliac bone. (D  –  F) Sacroiliac joint from a   Tnf     ARE/+   
mouse on the C57BL/6 background. The presence of a mononuclear infi  ltrate within the sacroiliac joint with an increased number of blood vessels is 
shown. The fi  brocartilagenous portion of the joint is invaded by mononuclear cells that protrude from the periost of the iliac bone into the BM. Paraffi  n 
sections are stained with hematoxylin and eosin. The boxes in B and E indicate the high-magnifi  cation areas shown in C and F, respectively. Bars: (A and D) 
500      m; (B and E) 200      m; (C and F) 50     m.   
    Table I.        Arthritis development following   Tnf      ARE    BM 
reconstitution of lethally irradiated recipients 
Donor genotype Recipient genotype Arthritis development
WT WT  0/20
  Tnf      ARE/+    WT 19/21
  Tnf      ARE/        ARE   TnfRI     /        WT 25/25
  Tnf      ARE/+     TnfRI      /       0/8
BM isolated from 2-mo-old female B6,129 mice (donor genotype) was engrafted 
into 6  –  8-wk-old syngeneic, lethally irradiated, female mice (recipient genotype). 
Assessment of arthritis development was based on histopathological evaluation of 
joint samples at 12 wk after transfer.334 MESENCHYMAL CELLS IN GUT/JOINT DISEASES | Armaka et al.
whereas   Tnf      ARE/+   TnfRI  fl  xneo/+     littermates developed intestinal 
pathology (  Table II  ). Furthermore, the spondylo  arthritic char-
acteristic of bilateral sacroiliitis observed in the   Tnf       ARE     model 
was also evident in the   ColVI-Cre Tnf       ARE/+   TnfRI  fl  xneo/fl  xneo     
mice examined at 40 wk of age but not in   Tnf       ARE/+   
TnfRI  fl  xneo/fl  xneo     control mice (four mice per group;   Fig. 3, 
E and F, respectively  ). Notably, introduction of the   ColVI-Cre   
transgene in the   Tg197 TnfRI  fl  xneo/fl  xneo     background also re-
sulted in the development of progressive infl  ammatory ar-
thritis starting at 5  –  6 wk of age and with 100% incidence 
(10 out of 10 mice), similar to the timing and course of 
disease seen in   Tg197   mice (  Fig. 3 G  ). Littermate control 
  Tg197 TnfRI  fl  xneo/fl  xneo     mice remained healthy even at 50 wk of 
age (15 out of 15 mice;   Fig. 3 H  ), further confi  rming the 
suffi   ciency of TNFRI signaling in mesenchymal cells for the 
development of TNF-driven arthritis. Southern blot anal-
ysis of tissue DNA from   ColVI-Cre Tg197 TnfRI  fl  xneo/fl  xneo     
mice confi  rmed the recombination of the TNFRI  fl  xneo   allele 
in joints, skeletal muscle, skin, gut, and heart (  Fig. 3 I  ). These 
fi  ndings demonstrate that mesenchymal cells are common 
primary targets for TNF in the development of infl  amma-
tory polyarthritis, Crohn  ’  s-like IBD, and anklylosing spondyli-
tis, and that selective expression of TNFRI on these cells is 
suffi   cient to orchestrate the complete development of such 
SpA-related pathologies. 
  ColVI-Cre TnfRI  fl  xneo/fl  xneo     SFs, IMFs, BM-derived macrophages, 
and CD11b  hi   splenic myeloid cells by fl  ow cytometric anal-
ysis of TNFRI expression, confi  rming Cre-mediated TNFRI 
reactivation in SFs and IMFs but not in other nonmesen-
chymal cell types such as myeloid cells (Fig. S4, available at 
http://www.jem.org/cgi/content/full/jem.20070906/DC1). 
ColVI-Cre  –  driven TNFRI expression in   ColVI-Cre Tnf       ARE/+   
TnfRI  fl  xneo/fl  xneo     mice was suffi   cient to induce a course of 
arthritic pathology similar to the   Tnf       ARE     mice, consisting of 
pannus formation with evident cartilage and bone erosions 
(  Fig. 3, A and B  ; and   Table II  ).   Flow cytometric analysis for 
the detection of TNFRI in SFs from individual   ColVI-Cre 
Tnf      ARE/+   TnfRI  fl  xneo/fl  xneo     mice confi  rmed reactivation of the 
TNFRI allele in these cells, whereas TNFRI expression was 
undetectable in the same cells from   Tnf       ARE      /      +   TnfRI  fl  xneo/fl  xneo     
mice (  Fig. 3 J  ). Histological examination of the ileum of 
  ColVI-Cre Tnf       ARE/+   TnfRI  fl  xneo/fl  xneo     mice revealed profound 
infl  ammatory changes consistent with the Crohn  ’  s  –  like dis-
ease phenotype of   Tnf       ARE     mice (  Table II  ). Intestinal 
pathology in the   ColVI-Cre Tnf      ARE/+   TnfRI  fl  xneo/fl  xneo     mice 
consisted of mucosal abnormalities with intestinal villous 
blunting and broadening, and mucosal and submucosal in-
fi  ltration of infl  ammatory cells with characteristics typical of 
transmural infl  ammation (  Fig. 3 C  ). None of the   Tnf      ARE/+   
TnfRI  fl  xneo/fl  xneo     littermates exhibited signs of disease (  Fig. 3 D  ), 
    Figure 2.         Mesenchymal cells from   Tnf      ARE     mice are activated before disease onset.   (A) Representative gelatin zymogram showing MMP9 and 
MMP2 secretion either from SFs (left) or IMFs (right) derived from WT and   Tnf    ARE/+    4-wk-old mice. (B) Representative semiquantitative RT-PCR for MMP3 
and TIMP1 expression in SFs (left) or IMFs (right) derived from WT and   Tnf    ARE/+    4-wk-old mice. WT cells treated with TNF were used as a positive control 
in A and B.     JEM VOL. 205, February 18, 2008  335
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early marker of SF and intestinal subepithelial fi  broblast acti-
vation by TNF. Increased levels of MMP3 and other MMPs 
have been reported in CD (  24  ) and arthritic patients (  25  ). 
Sustained perturbations on MMP expression are now strongly 
  Collectively, the data in this study demonstrate that mes-
enchymal cell targeting by TNF represents a common patho-
genic mechanism in chronic infl  ammatory joint and intestinal 
diseases. Deregulated MMP expression was detected as an 
    Figure 3.         TNFRI-expressing mesenchymal cells are suffi  cient targets of pathogenic TNF.   (A  –  D) Histological examination of joint (8-wk-old) and 
ileal (16-wk-old) sections from   ColVI-Cre Tnf     ARE/+  TnfRI fl  xneo/fl  xneo    (A and C) and   Tnf     ARE/+  TnfRI fl  xneo/fl  xneo    mice (B and D). (E and F) Histological examination 
of sacroiliac joint sections from 10-mo-old   ColVI-Cre Tnf     ARE/+  TnfRI fl  xneo/fl  xneo   (E) and   Tnf     ARE/+  TnfRI fl  xneo/fl  xneo    mice (F). (G and H) Histological examination 
of joint sections from 7-wk-old   ColVI-Cre Tg197 TnfRI  fl  xneo/fl  xneo    (G) and   Tg197 TnfRI  fl  xneo/fl  xneo    mice (H). Paraffi  n sections were stained with hematoxylin and 
eosin. Bars: (A, B, G, and H) 600     m;  (C – F)  100      m. (I) Southern blot analysis of BamHI-digested tissue DNA from   ColVI-Cre TnfRI  fl  xneo/fl  xneo    mice for detec-
tion of the recombined loxP   TnfRI   allele. (J) Flow cytometric analysis or the detection of TNFRI expression in   ColVI-Cre Tnf     ARE/+  TnfRI fl  xneo/fl  xneo    SFs  derived 
from the cultures of individual mice. White lines indicate that intervening lanes have been spliced out.     336 MESENCHYMAL CELLS IN GUT/JOINT DISEASES | Armaka et al.
The ColVI promoter cassette used for the generation of ColVI-Cre mice 
was provided by G. Bressan (University of Milano, Milano, Italy). All mice 
were bred and maintained on C57BL/6J and on mixed C57BL/6J   ×   129S6 
or C57BL/6   ×   CBA genetic backgrounds in the animal facilities of the 
BSRC   “  Alexander Fleming  ”   under specifi  c pathogen-free conditions. All 
mice were used in accordance with the guidance of the Institutional Animal 
Care and Use Committee of BSRC   “  Alexander Fleming.  ”   
  BM transplantation.     BM transplantation experiments were performed as 
previously described (  12  ). 
  Cell culture.     SF cultures were established by enzymatic treatment as previ-
ously described (  1  ). IMF cultures were established by enzymatic treatment 
of terminal ilea (5 cm). In brief, the intestinal pieces were fl  ushed extensively 
with HBSS (Sigma-Aldrich)/2% FBS (Biochrome), and cut longitudinally. 
The epithelial layer was removed by incubation in DMEM/10% FBS-con-
taining collagenase XI (300 U/ml)/dispase (0.1 mg/ml; Sigma-Aldrich) for 
10 min at 30  °  C. The digested tissues were washed with HBSS/2% FBS 
and subjected to a second incubation with collagenase/dispase for 20 min 
at 30  °  C. The mucosal samples were then washed and cultured at 37  °  C in a 
humidifi  ed CO  2   incubator in DMEM (Invitrogen) supplemented with 10% 
FBS, 1% nonessential amino acids, 100 U/ml penicillin, 100      g/ml strep-
tomycin (Invitrogen), and 1      g/ml amphotericin B (Sigma-Aldrich). Cells 
were used after three passages. The purity of myofi  broblast cultures was 
determined by fl  ow cytometric detection of CD90 (BD Biosciences) and 
     SMA (Sigma-Aldrich) expression. The generation of BM-derived macro-
phages was performed as previously described (  9  ). 
  Gelatin zymography and Western blotting.     In brief, synchronized cells 
were grown in confl  uence on 10-cm plates in the presence or absence of 
20 ng/ml of mouse TNF. Cell extracts (in 50 mM Tris-HCl [pH 7.4], 150 mM 
NaCl, 0.1% SDS, 1% Triton X-100, 2      g/ml leupeptin, 2      g/ml aprotinin, 
1mM PMSF) were collected at the time points indicated in the fi  gures. The 
samples were sonicated and stored at      70  °  C until use. 20   μ  g of total protein 
per sample was analyzed on 8% SDS-PAGE containing 1 mg/ml of gelatin 
under nonreduced conditions, at 4  °  C, and at a constant voltage (100 V). 
The gel was rinsed for 60 min in 2.5% Triton X-100 and incubated in MMP 
activation buff  er (50 mM Tris-HCl [pH 7.5], 5 mM CaCl  2  , 0.02% NaN  3  , 
1      M ZnCl  2  ) for 36 h at 37  °  C with constant shaking. Gels were stained for 
30 min with 0.5% Coomassie blue R250 and destained in 40% methanol/10% 
acetic acid. The gels were stored either dried or in water/20% glycerol. The 
specifi  city of reaction was tested with the use of specifi  c inhibitors that were 
added to the activation buff  er (10 mM EDTA and 0.1 mM phenantroline). 
For detection of actin, 20 mg of total protein per sample was analyzed on 
8% SDS-PAGE, electrotransfered in nitrocellulose membrane, and detected 
with Western blot analysis using polyclonal antibodies against actin (Santa 
Cruz Biotechnology, Inc.). 
  RNA isolation and RT.     RNA was isolated with TRI  zol   (Invitrogen). RT 
to complementary DNA was performed with 12   μ  g RNA by MMLV-RT 
(Promega) at a fi  nal volume of 20      l, according to manufacturer  ’  s instructions. 
The volume of the reaction was increased to 50   μ  l     and the dilutions used in reac-
tions were always performed in accordance with the housekeeping gene content. 
The sequences of the primers are as follows: MMP3 sense,  5     -CCACAGACTT-
GTCCCGTTTCC-3     ; MMP3   antisense,   5     -GAGTCCTGAGAGATTT-
GCGCC-3     ; TIMP1   sense,   5     -ACAAGTCCCAGAACCGCAGTA-3     ; 
TIMP1   antisense,   5     -  GGACCTGATCCGTCCACAAAC-3     ;      2 micro-
globulin (     2  M)   sense,   5     -  TTCTGGTGCTTGTCTCACTGA-3     ; and      2  M   
antisense,   5     -  CAGTATGTTCGGCTTCCCATTC-3     . The annealing tem-
perature for all primers was 53  °  C for 30 cycles. Product sizes were as follows: 
MMP3, 237 bp; TIMP1, 234 bp; and      2  M,   104 bp. 
  Online supplemental material.     Fig. S1 shows the histopathological 
manifestations of BM chimeras. Fig. S2 shows the immunohistochemical 
detection of MMPs in mesenchymal cells of   Tnf       ARE     mice before disease onset. 
implicated in various processes central to infl  ammation and 
immunity, such as cytokine and chemokine production, leu-
kocyte recruitment, and tissue repair (  26  ). It is thus possible 
that, in susceptible hosts, dysfunctional responses to tissue in-
jury, infections, or other environmental stimuli may lead to 
sustained TNF/TNFRI-dependent activation of mesenchy-
mal cells. Failure to regulate these proinfl  ammatory and tis-
sue-repair activities may be responsible for driving the 
transition of acute-to-chronic tissue infl  ammation and fi  bro-
sis (  15  ). SFs do play a critical role in these processes, as they 
have been suggested to be capable of propagating both in-
fl  ammation and joint destruction in rheumatoid arthritis (  27, 
28  ). An equally important role may be played by the intestinal 
subepithelial myofi  broblast, which is also considered impor-
tant in maintaining tissue architecture, regulating infl  amma-
tion, and repair in the gut (  29  ). Intestinal infl  ammation has 
also been prominently linked to epithelial barrier dysfunction 
(  13  ). It was recently demonstrated that NF-     B-defi  ciency sen-
sitizes epithelial cells to TNFRI-dependent apoptosis, linking 
innate immunity to intestinal infl  ammation (  30  ). It will also 
be interesting to investigate whether TNFRI-mediated sig-
naling on IMFs may contribute to epithelial barrier dysfunc-
tion in CD. 
  The identifi  cation of mesenchymal cells as a cellular sub-
set linking joint and intestinal pathologies provides an alter-
native cellular basis to understand the common occurrences 
of these pathologies in humans, as well as the remarkable re-
sponse of a signifi  cant number of patients to anti-TNF ther-
apies (  6  ). Mesenchymal cell replacement by stem cell or BM 
transplantation may off  er future therapeutic approaches for 
the resolution of chronic infl  ammatory processes. The iden-
tifi  cation of TNF-responsive mesenchymal cells as dominant 
contributors to joint and gut infl  ammatory diseases suggests 
that attenuation of the TNFRI pathway in these cells or their 
precursors may hold promise for more rational and eff  ective 
therapeutic interventions. 
  MATERIALS AND METHODS 
  Mice.     The generation of   Tg197   (  7  ),   Tnf       ARE     (  9  ), and mutant mice carrying 
a conditional gain-of-function allele for   TnfRI   (  TnfRI  fl  xneo     mice) have been 
previously described (  23  ).   TnfRI      /        (  14  ) and   Z/EG   (  22  ) mice were pur-
chased from the Jackson Laboratory.   ROSA26  fl  x/+     (  21  ) mice were provided 
by P. Soriano (Fred Hutchinson Cancer Research Center, Seattle, WA). 
    Table II.        Incidence of arthritic and intestinal pathology in 
  Tnf      ARE/+  TnfRI fl  xneo/fl  xneo  ColVI-Cre   mice and littermates 
Genotype
Incidence of pathology
Arthritic Intestinal
wk 8 wk 16 wk 8 wk 16
  Tnf      ARE/+   TnfRI fl  xneo/fl  xneo   
0/7  
  0%
0/10  
  0%
0/7  
  0%
0/10  
  0%
  ColVI-Cre Tnf      ARE/      +      
 TnfRI fl  xneo/fl  xneo    
5/5  
  100%
21/21  
  100%
5/5  
  100%
21/21  
  100%
  Tnf     ARE/+   TnfRI fl  xneo/+   
5/6  
  83%
4/4  
  100%
4/6  
  66%
4/4  
  100%JEM VOL. 205, February 18, 2008  337
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